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a b s t r a c t
Inclusion of the central nervous system (CNS) in the course of chronic lymphocytic leukae-
mia (CLL) is rare. At the moment no risk factors or proven treatment methods are known.
The disease is described both in its early phase and during its acceleration period, thus it has
been suggested that there might be independent mechanisms inﬂuencing the development
of this condition. As there are no uniﬁed diagnostic procedure algorithms each patient needs
to be assessed individually. CLL can manifest mostly in elderly people, for whom a possibility
of development of neurological disorders with their aetiology different from leukaemia,
should also be taken into consideration. The thesis presents a group of seven patients with
CLL with CNS inﬁltration. Patients with prolymphocytic leukaemia, Richter's transformation
and the original location of leukemic inﬁltration within the eye socket constitute an
especially interesting case.
© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
Available online at www.sciencedirect.com
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Chronic lymphocytic leukaemia (CLL) is a disease that is
characterised by a clonal proliferation and accumulation of
mature B lymphocytes in peripheral blood, bone marrow and
lymphoid tissues [1]. A different location is very rare and is
usually connected with the skin and central nervous system* Corresponding author at: Department of Haematooncology and Bon
Unit Medical, Medical University of Lublin, Staszica 11 Str., 20-081 Lu
E-mail address: agnieszka.szymczyk.med@wp.pl (A. Szymczyk).
https://doi.org/10.1016/j.pjnns.2017.10.012
0028-3843/© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish N(CNS) [2]. Despite that fact, CLL belongs to the type of
proliferation in which the central nervous system involvement
(CNSi) is seldom considered, contrary to infective, immuno-
logical complications or transformation of Richter syndrome
(RS) [3]. At the moment no CNSi risk factors or uniﬁed proven
treatment methods are determined. It results mainly from a
small group of patients with such condition (in the last
40 years fewer than 100 cases of CLL and CNSi have beene Marrow Transplantation, Independent Clinical Transplantology
blin, Poland.
eurological Society.
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meninges and cranial nerve, but extremely rarely with the
brain and spinal cord. What is characteristic is a highly diverse
clinical manifestation, although the neurological symptoms
can be observed in a small number of patients, and in case of
histologically conﬁrmed affection of meninges, it concerns
only 1% of the examined [4,5]. Thus, we can probably talk about
a signiﬁcant underestimation of the number of patients with
this illness.
1.1. Objective
The objective of this research paper is a retrospective analysis
of patients with CLL/SLL and CNS inﬁltration.
2. Materials and methods
The analysis included patients with CLL/SLL diagnosed in the
years 2007–2016. In this timeframe, 223 CLL/SLL patients were
treated. Apart from patients with inclusion of the CNS in the
course of CLL, 102 women and 114 men at a median age 64.9
years (34–87 years), Rai stage 0–4 and Ann Arbor II-IV clinical
stage, has been observed or treated.
Based on a retrospective analysis we have conducted an
assessment of the clinical, biological and radiological param-
eters (magnetic resonance imaging; MRI, computed tomogra-
phy; CT) of the patients with CLL and CNSi, in the period from
February 2007 to March 2015. Five patients had lumbar
puncture done with the collection of cerebrospinal ﬂuid
(CSF). The CSF tests included the cytological, biochemical,
cytometric and microbiological evaluation. In three cases
material for histopathological tests was also collected. Clinical,
immunophenotyping and genetic parameters of the CLLTable 1 – Clinical characteristics, immunological and genetic pa
Patient 1 Patient 2
(CLL/PLL)
Patient 3 P
Age (year)/sex 63/M 43/M 54/M 70/F
Rai clinical stage 0 2 2 2 
Stage of disease
during CNSi
Stable disease Progression (tran
into
Stable disease Stable disease
Prior therapy for
CLL
0 0 COP, CHOP,
FC, F,
ofat
+ id
0
Genetic
aberrations
Not found Not done Not found del1
ZAP-70/CD38 ZAP-70/CD38+ Not done ZAP-70/
CD38+
ZAP
Time between
CLL and CNSi
diagnosis
(month)
3 2 71 27 
Follow up
(month)
38 3 1 2 
Status at last
follow up
Alive Death Death Dea
C – cyclofosfamide; O – vincristine; H – doxorubicin; P – prednisone; F – ﬂpatients at the moment of diagnosis of CNSi are shown in
Table 1.
3. Results
Seven patients with CLL, who were diagnosed with CNSi were
analysed. They were four men and three women aged between
43 and 76 years old. They were in the stadium 0–3 according to
Rai et al. classiﬁcation. The CNSi diagnosis was determined
based on the ﬂow cytometric analysis of the CSF in ﬁve
patients and histopathological examination in three patients
(in two patients, based on the autopsy: patient nos. 3 and 5).
Three patients received intrathecal treatment, one had a
neurosurgical procedure (total resection of the tumour)
followed by radiotherapy. Three patients due to their serious
general condition did not receive the cytostatic treatment. All
patients were radiologically diagnosed (MRI/CT) and they
manifested diverse neurological symptoms. Neurological
disorders, radiological image, received treatment of patients
with CLL and CNSi and test results of the cerebrospinal ﬂuid
are shown in Tables 2 and 3 and Figs. 1 and 2.
4. Discussion
Affecting the CNS in the course of non-Hodgkin's lymphomas
(NHL) is observed in approx. 8% of patients [6,7]. It is mostly
observed in case of the most aggressive histopathological
types, such as e.g. Burkitt lymphoma or lymphomas of speciﬁc
locations (testicular lymphoma, lymphoma around the para-
nasal sinuses) [8,9]. There are several hypotheses attempting
to explain the mechanisms leading to affecting the CNS in the
course of CLL. One of them indicates a possibility of therameters of patients with CLL at the time of CNSi diagnosis.
atient 4 Patient 5 Patient 6 Patient 7
 76/K 56/M 70/K
2 0 3
sformation
 PLL)
Progression
(Richter's
transformation)
Progression Stable disease
umumab
elalisib
B, BR 0 0
1q Not found Not found Not found
-70/CD38 ZAP-70/CD38 ZAP-70/CD38+ ZAP-70+/CD38+
0 0 0
1 126 3
th Death Alive Death
udarabine; B – bendamustin; R – rituximab.
Table 2 – Neurological symptoms, radiological image and treatment of patients with CLL/SLL and CNSi.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Localisation in CNS
(neuroimaging)
No changes Inﬁltration
of
hemispheres and
cerebellum
Inﬁltration
of
cavernous
sinus
No changes Inﬁltration
of the
corpus
callosum
and the
membrane
lining the
ventricles
Nodular
mass in the
left side
part of eye
socket
Inﬁltration
of cavernous
sinus
Neurologic
symptoms
Headache,
behaviour
disorders
Bilateral
paresis,
dysarthia
Headache,
slowing
down,
orientation
disorders
Headache,
orientation
disorders
Slowing
down,
orientation
disorders
Impaired
visual
activity and
limitation
of
movement
of the left
eyeball
Third left
nerve palsy
Treatment of CNSi Mtx/Ara-C/
PDN
intrathecal,
radiotherapy Mtx/Ara-C/
PDN
intrathecal
NA Mtx/Ara-C/
PDN
intrathecal
NA Tumour
resection,
radiotherapy NA
Response to
treatment
CR Progression NA Progression NA CR NA
Mtx – methotrexate, Ara-C – cytosine arabinoside; PDN – prednisone; CR – complete remission; NA – not applicable.
Table 3 – Test results of the cerebrospinal fluid.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
CSF cellularity/ml 41 240 ND 80 ND 56 67
Percentage of
leukemic cells in
CSF
85.0% 87.6% – 67.0% – 49.0% 52.0%
Immunofenotype CD19+/CD5+/CD23+ CD19+/CD
5/CD23
– CD19+/CD5
+/CD23+
– CD19+/CD5
+/CD23+
CD19+/CD5
+/CD23+
Red blood cells/ml 0 0 – 0 – 0 0
Protein (mg/dl) 88.0 ND – –
Glucose (g/dl) 72.0 ND – –
Microbiology study Negative ND – Negative – Negative Negative
ND – not done.
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through damaged blood vessels and perineural sheath of the
cranial nerves and spinal nerve roots [6]. CLL is a disease that is
characterised by complex immunological disorders, concern-
ing both the cellular and humoral response. CNS and the
peripheral nerves might be places connected with the
leukemic complications [10,11]. De Vito et al. described
paraneoplastic syndrome, which is present in a patient with
small lymphocytic lymphoma (SLL), involving demyelination
of the CNS. Conducted diagnostic tests: MRI, CSF test did not
indicate the leukemic inﬁltration. According to the authors, it
is the only such case described, connected with the presence of
unknown antibodies [12]. CLL can manifest mostly in elderly
people, for whom a possibility of development of neurological
disorders with their aetiology different from leukaemia,
should also be taken into consideration. In an extensive workdedicated to the neurological disorders in patients with CLL,
Silva describes a range of causes that may potentially trigger
them. Those include i.e. retinopathy, optic neuropathy,
secondary brain tumours (meningiomas, gliomas), intracrani-
al bleeding, infections, neurotoxicity caused by prescribed
drugs [13]. It might seem that CNSi in the course of CLL should
appear in leukaemia progression phase. Moazzam et al. based
on one of largest study demonstrated a lack of relevant
connection of this pathology with more aggressive course of
CLL, age and sex of the patients, clinical stage and type of
neurological symptoms [3]. In our study (four patients) the
leukemic inﬁltration of the CNS most often occurred in the
period of acceleration (i.e. prolymphocytic leukaemia, Rich-
ter's syndrome), but also in the phase of stabilisation and even
in the moment of diagnosis of CLL. This may prove an
existence of different mechanisms inﬂuencing the develop-
Fig. 1 – Nodular mass in the left side part of eye socket (patient 6).
Fig. 2 – Infiltration of the corpus callosum and the membrane lining the ventricles (patient 5).
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which are characteristic of the natural course of leukaemia. As
can be seen, CNSi may appear in all stages of the disease,
regardless of its dynamics.
A lot of controversies is posed by the issue of diagnosing the
CNSi, which at the moment is based on morphological,
cytometric [14], and cytogenetic [15] evaluation of the CSF cells
and imaging studies, referred to as MRI. A certain amount of
caution is advised in clear interpretation of the presence of
lymphocyte population of monoclonal antibodies in CSF. It does
not have to constitute a clear proof of leukemic inﬁltration of
the CNS. It is believed that in certain situations they may move
to CSF and similarly to normal lymphocytes, they may be
‘‘mobilised’’ to the inﬂammatory foci [16].
Due to that fact, a possible presence of the inﬂammatory
processes or autoimmune complications must be taken into
consideration in every situation. Another possible mechanism
is ‘‘contamination’’ of CSF by the leukemic cells during lumbar
puncture. In every case studied by us, the CSF indicated
presence of a monoclonal population of cells with a phenotype
CD19+/CD5+/CD23+ (apart from the patient with PLL), therewas no presence of erythrocytes and the results of microbio-
logical tests were negative. In three patients a histopatholog-
ical study of the inﬁltrated tissue was conducted. It was a base
of diagnosis for patient nos. 3 and 5. Radiological changes in
case CNSi in patients with CLL are described as diffused
inﬁltration of the meninges by a thin layer of leukemic cells or
intracerebral inﬁltrates. At the same time, it is indicated that
there are no visible changes in the imaging studies [3]. All that
results in many difﬁculties in diagnosing CNSi. Above all, the
doctor is required to have an awareness of the possible
(although rarely considered) location of the disease, to conduct
all possible tests and appropriate interpret them.
In the course of CLL a transformation into Richter's
syndrome and prolymphocytic leukaemia is particularly
signiﬁcant. RS is a rare complication of CLL involving an
evolution into more aggressive form of lymphoma [17]. In case
of ‘‘classic’’ form of RS, it is a diffuse B-cell large lymphoma
(DLBCL) [18], and a lot less often, into a Hodgkin lymphoma
(HL) [19]. RS is typically present in the lymph nodes and bone
marrow. Location outside of nodes concerns about 41% of
cases. RS in CNS was described in very few cases, in the area of
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the leukemic inﬁltration was detected in the cavernous sinus.
RS was developed after 71 months of the course of the disease
and many types of treatments (COP, CHOP, FC, F, ofatumumab
+ idelalisib), which may constitute a voice in the discussion
regarding the inﬂuence of the previous treatments in the
development of RS. The patient died soon after ﬁnding the
changes in CT (the ﬁnal diagnosis of DLBCL was determined
during the autopsy), which suggests especially poor prognosis
of RS in CNS [21]. B-cell prolymphocytic leukaemia (B-PLL) is a
rare proliferation, characterised by a very aggressive clinical
course, resistance to the applied chemotherapy and a poor
prognosis. It may both appear de novo and be a transformation
of CLL diagnosed earlier [23]. Affection of the CNS in the course
B-PLL and CLL/PLL is known only from descriptions of
individual cases [24]. In our work we presented a patient, in
whom after two months from the diagnosis of classic form of
CLL, there was a transformation into B-PLL (CLL/PLL). Along
with the appearance of the neurological symptoms, hyperleu-
kocytosis with 70% rate of prolymphocytes in peripheral blood
and increasing splenomegaly was found. Tatarczuch et al.
suggest that cancerous prolymphocytes may demonstrate a
speciﬁc tropism to the CNS, the mechanism of which is not yet
sufﬁciently understood [25]. At the same time, according to
some scholars a signiﬁcant number of the leukemic cells in the
peripheral blood predisposes to inﬁltration of the CNS as a
result of a normal perfusion or extravasation [24]. Hyperleu-
kocytosis is a known risk factor of the CNS inﬁltration in the
course of acute myelogenous leukaemia and acute lympho-
cytic leukaemia. It is pointed out that the expression of
neuronal adhesion molecule is also signiﬁcant in this process
[26]. The case of the patient, who was diagnosed with orbit
involvement in CLL is also very interesting. In the available
literature there are only several cases regarding that subject
[27]. The patient presented by us was observed with the
gradual growth of the eyeball exophthalmos and swelling of
the upper eyelid. After three years of observation, due to
intensifying of the aforementioned symptoms, after MRI
evaluation orbital tumour was diagnosed and the patient
was qualiﬁed for neurosurgery. Tumour resection was
performed, and histopathological examination of the tissue
revealed the presence of inﬁltration of small cell with
phenotype CD19+/CD5+/CD23+. Based on the simultaneous
changes in blood morphology and after the clinical evaluation
CLL stage 0 according to Rai et al. was diagnosed. Orbital
lymphomas are the only approx. 1% of all NHLs [28] and they
are most often diagnosed primary orbital tumours (this applies
to patients above 60 years of age) [29]. The most frequently
observed histopathological types are extra-nodal marginal-
zone B-cell lymphomas of mucosa-associated lymphoid
tissue-MALT (57%) and follicular lymphomas (19%), while less
frequently, diffuse large B-cell lymphomas and mantle cell
lymphomas (MCL). Orbital lymphomas may be either isolated
or form part of a systemic disease (30–35% of cases) [30]. The
differential diagnosis should also take into account chronic
dacryoadenitis, Wegener granulomatosis, idiopathic inﬂam-
matory pseudotumour, orbital lymphoid hyperplasia, orbital
sarcoidosis. Diagnostic tests include ultrasound scan, CT and
MRI. Lumbar puncture to evaluate the CNS should also be
considered. The treatment usually involves the radiotherapyand/or complex chemotherapy. According to some authors
orbital lymphomas in the course of a systemic disease have a
better prognosis than those with a local location [31].
At the moment there is no single therapeutic treatment
algorithm for patients with CLL and CNSi. Many drugs used in
the standard systemic treatment do not cross the blood–brain
barrier. In the case of leukemic inﬁltration of the meninges, the
most commonly used are corticosteroids, intrathecal metho-
trexate in monotherapy and/or in combination with cytar-
abine and dexamethasone and radiotherapy. Well-known are
the opinions conﬁrming, as well as questioning the effective-
ness of such treatment [24]. Methotrexate is a drug with poor
capacity of passing through the blood-brain barrier. Achieving
the therapeutic concentration in CSF is possible with high
intravenous (iv) doses or intrathecal injection (then it achieves
a particularly beneﬁcial, uniform concentration in the sub-
arachnoid space) [32]. There are known reports of beneﬁcial
effects of intrathecal injection therapy, which were, unfortu-
nately, not continued and conﬁrmed in further studies [33].
While the intrathecal administration of drugs is often effective
for treating leukemic inﬁltration of the meninges, it does not
seem to be sufﬁcient for intracerebral inﬁltration, having a
particularly high sensitivity to radiotherapy [3]. Knop et al.
decided to give iv ﬂudarabine to two patients with CLL and
CNSi, while sacriﬁcing the intrathecal treatment and radio-
therapy. Each patient achieved complete eradication of
leukemic cells with CSF and remission of neurological
symptoms, and in the patient with symptoms of systemic
disease, regression of nodal changes and normalisation of
peripheral blood. Importantly, there were no signs indicating
neurotoxicity of ﬂudarabine. According to the authors, these
results may indicate the possibility of application of the
ﬂudarabine iv in CLL patients with CNS involvement, who at
the same time have an advanced systemic disease [34].
Questions about the role of rituximab in the treatment of
CNS leukemic changes in the course of CLL are still to be
answered. Pharmacokinetic studies, when administered iv,
showed its signiﬁcantly lower concentration in CSF compared
to the serum (approx. 1% of the value of the serum
concentration). It is caused by a large molecular weight of
the rituximab (146 kDa) limiting its penetration to the CNS,
even at damaged blood–brain barrier [35]. The alternative
would be to provide rituximab intrathecally, but at the
moment we do not have any information on tests to be taken
of such treatment in patients with CLL and CNSi. We know,
however, instances of application of this monoclonal antibody
with other drugs. Faivre et al. described three patients with
neurological disorders and leukemic cells present in the CSF.
Patients received 5–6 courses of bendamustine and rituximab
(BR) as a result of which all patients achieved complete
regression of the lesions [36]. Benjamini et al. presented the
case of a 44-year-old patient with CLL and leukemic inﬁltrates
in the eye socket and CSF. Initially, it was decided to
administer methylprednisolone with rituximab and then,
with complete success, 3 courses of ﬂudarabine with cyclo-
phosphamide and rituximab (FCR). The authors suggest that
there is a potential ability to use systemic chemioimmu-
notherapy in this highly selected group of patients [37]. Hanse
et al. described ﬁve CLL patients with clinical signs of CNS
involvement in the course of leukaemia. The withdrawal of
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and intrathecal therapy. However, no complete eradication of
leukemic cells with CSF was determined. Nevertheless, three
patients were tested at follow-up without symptoms for two
and three, and one for the next seven years. According to the
authors, asymptomatically extending presence of leukemic
cells in the CSF is not necessarily an automatic indication for
further treatment [14]. Perhaps one should, at least in some
cases, wait for the possible re-emergence of neurological
disorders. These ﬁndings call into question the suggestion of
some authors that the location of leukemic changes in the CNS
in the course of CLL is in any case unfavourable prognostic
factor. Three patients presented in our work have been treated
with intrathecal treatment and one with radiotherapy (pre-
ceded by a neurosurgical procedure). Unfortunately, the other
three died before treatment. Recently, there were reports
about the possibility of penetration of the blood-brain barrier
by the kinase inhibitors. Russwurm et al. described a patient
with relapsed form of CLL in the CNS, after failure of systemic
therapy with cytarabine and mitoxantrone and intrathecal
methotrexate. Dasatinib was used at a dose of 70 mg 2 times a
day, giving a total regression of numerous lesions in the CNS.
This spectacular effect is particularly worth noticing as the
pharmacokinetic studies indicate relatively small, compared
to the plasma, concentration of the drug in the CSF (5–28%)
[38]. Wanquet et al. in his publication presented a very
interesting proposition of possibly effective treatment of CNSi
using ibrutinib. In four patients the disappearance of neuro-
logical symptoms and changes in CSF as well as a normal-
isation to the radiological image were obtained after applying
standard dose of medicine (420 mg/d) [39]. The effectiveness of
ibrutinib in this extremely difﬁcult clinical situation is also
conﬁrmed by Tam et al. [40].
The prognosis of CLL patients with CNS involvement is not
easy to deﬁne. Based on available literature data, Moazzam
et al. determined the average period of time since the
appearance of neurological symptoms to death to approx. 12
months. The average time from diagnosis CLL with CNS
involvement was 2.62 years. However, the authors failed to
accurately determine the duration of the obtained remission
and the number of patients with disease recurrence in the CNS
[3]. In our material the CNSi prognosis can be described as
extremely unfavourable. Five patients died within a very short
period of time (1–3 months). Presumably, it was also
inﬂuenced by the transformation in the RS and PLL. Nonethe-
less, two patients, after a complete remission due to the
treatment, is still under the clinical observation.
5. Summary
CNS involvement in the course of CLL is rare and usually
unexpected, as a result the knowledge that we have at the
moment on this issue is certainly not sufﬁcient. In each case
with CLL with unexplained neurological disorders, CNS
involvement should be considered in the course of the
underlying disease and the basic diagnostic radiology (MRI)
and CSF examination (cytological, immunophenotyping,
cytogenetics) should be performed, with the knowledge of
all the constraints and concerns they bring. CNSi may occur atany stage of the disease, either as the ﬁrst manifestation or
after several years of treatment, often in the phase of
progression or transformation into more aggressive clinical
form (prolymphocytic leukaemia, Richter's syndrome). This
may suggest the existence of independent mechanisms
affecting the development of this complication. Lack of
uniform algorithms means that each patient requires an
individual assessment, also in terms of comorbidities. The
preferred therapeutic effect can be obtained after the
intrathecal treatment (MTX, Ara-C) and radiation therapy. It
is probably a bad prognosis for the complication of CLL, often
leading to death. It seems, however, that at the moment there
are no indications for the use of routine CSF or MRI in all
patients with CLL.
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